Ondine Biomedical's Steriwave Enters Swiss Medical Trial

Ondine Biomedical Inc. announces the initiation of an independent clinical study on Steriwave at University Hospital Zurich (USZ), marking the first use of its nasal decolonization technology in Switzerland. This research, led by Professor Dr. Harald Essig, investigates the efficacy of Steriwave in reducing preoperative nasal microbes to combat surgical site infections (SSI).

Steriwave employs antimicrobial photodynamic therapy (aPDT), a light-activated process destroying pathogens rapidly. This technology offers an immediate, five-minute solution to preoperative nasal sanitation, distinguishing it from traditional antibiotics.

USZ's study complements Steriwave's established effectiveness in Canada and the UK, supporting its role in enhancing patient safety and addressing antimicrobial resistance. Carolyn Cross, CEO of Ondine Biomedical, emphasizes its potential as a pivotal advancement in infection prevention.